News

Public · Published

New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation

Milestone Pharmaceuticals announced that CARDAMYST nasal spray converted approximately two-thirds of patients with recurrent symptomatic PSVT after prior catheter ablation to normal heart rhythm within 30 minutes. The result came from a subgroup analysis of the Phase 3 RAPID trial, and the company said it would be presented at the AHA Scientific Sessions on November 7.

Published:

Updated:

What happened

Milestone Pharmaceuticals announced that CARDAMYST nasal spray converted approximately two-thirds of patients with recurrent symptomatic PSVT after prior catheter ablation to normal heart rhythm within 30 minutes. The result came from a subgroup analysis of the Phase 3 RAPID trial, and the company said it would be presented at the AHA Scientific Sessions on November 7.

Confirmed

Global impact / market context

The findings point to a possible treatment option for adults whose rapid heart rhythm episodes return after ablation, potentially addressing a need for care outside emergency rooms. If the result supports broader use, CARDAMYST could contribute to Milestone’s sales, though the reported subgroup was small.

Analyst inference

CARDAMYST is already FDA-approved to convert acute symptomatic PSVT episodes to normal rhythm in adults, so this update concerns evidence in a specific group rather than a new approval. Investors may view the subgroup result as relevant to the medicine’s potential reach, but it does not establish commercial uptake or revenue.

Analyst inference

What to watch

  1. At the November 7 AHA presentation, watch for the subgroup’s size and full results; these details would help assess how much weight to place on the reported response. Analyst inference
  2. The article describes the group as small, so watch for further evidence in patients with prior ablation before treating this result as representative of routine care. Analyst inference
  3. Watch whether physicians use CARDAMYST for recurrent episodes after ablation; wider use could increase prescriptions and sales, while limited adoption would constrain that potential. Analyst inference

Evidence